Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related ...

EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...

The human body has some brutal survival limits, and medicine has documented them in detail. Certain body parts can be removed ...

An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...

After being diagnosed with a rare bile duct cancer, a dad feared his toddler son might grow up without him until his cousin ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligence-based TARIO-2 model identified spatial tumor ...

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...

Compared to people without liver steatosis, those with the condition had greater noncalcified coronary plaque burden and ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper ...

Scientists at The Hormel Institute say they have made new discoveries about a protein that could play a key role in how liver ...

A pioneering Chinese study has found that a new drug cocktail administered before surgery, can nearly double the time patients with a deadly form of liver cancer live without the disease returning.